Skip to main content
OpenTrials
Completed

NCT Number: NCT01335347

Safety Study of an Oral Vaccine to Prevent Avian Influenza

The purpose of this study is to demonstrate the safety and immunogenicity of an oral vaccine to prevent avian influenza. Volunteers will receive either one or two doses of research vaccine or placebo as part of this study.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–49 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

San Diego, California, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • In good health as established by medical history, physical examination and laboratory testing at the time of enrollment.

Exclusion criteria

  • Has had any other vaccines within the past 8 weeks.
  • Has had prior H5 avian influenza investigational vaccine.
  • Current history of chronic alcohol consumption and/or illicit and/or recreational drug use.
  • History of autoimmune related disease.
  • History of any confirmed or suspected immunodeficient or immunosuppressive condition (no congenital or acquired condition that impedes normal immune response, no concurrent immunosuppressive therapy).
  • Positive serology for HIV, HCV, or HBV.
  • Previous serious reactions to vaccination such as anaphylaxis, respiratory problems, hives or abdominal pain.
  • History of irritable bowel disease or other inflammatory digestive or gastrointestinal conditions that could affect the intended distribution or safety evaluation of an orally administered vaccine targeting the mucosa of the small intestine.
  • Use of proton pump inhibitors (Nexium, Prilosec) that substantially increases stomach pH.
  • Stool sample with occult blood at baseline exam

Treatment and study plan

ND1.1

Biological

adenovirus with the dsRNA adjuvant, dried and put into capsules

Other names: Ad-HA-dsRNA

Placebo control

Biological

Capsules of the same size and shape as experimental groups

Primary outcomes

  1. Frequency or severity of vaccine related events as measured through reported AEs

    Time frame: up to 1 year

Secondary outcomes

  1. Magnitude of humoral immune responses to avian influenza as measured by functional assays

    Time frame: up to 1 year

  2. Magnitude of cellular immune responses to avian influenza as measured by functional assays

    Time frame: up to 1 year

Sponsors and collaborators

Lead sponsor

Vaxart

Industry

Registry information

Official study title

A Dose Escalation Phase 1 Safety and Immunogenicity Study of an Oral Viral Vector Vaccine Encoding Avian Influenza H5N1 Hemagglutinin Protein and dsRNA Adjuvant in Healthy Adults

Acronym: H5N1

Important dates

Study start
2011
Primary completion
2012
Study completion
2012
First posted
Apr 14, 2011
Registry last updated
Jan 3, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.